[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"grade-2-follicular-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:grade-2-follicular-lymphoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,70,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100589005","phase-2-pirtobrutinib-and-mosunetuzumab-for-the-treatment-of-relapsedrefractory-grades-1-3a-follicular-lymphoma-promote-fl-trial-100589005",false,"NCT06948786","Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed\u002FRefractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial","PROMOTE-FL: Pirtobrutinib and Mosunetuzumab to Enhance Treatment Efficacy for Patients With Relapsed\u002FRefractory Follicular Lymphoma","Inclusion Criteria:\n\n* Ability to understand, willing, and capable of signing a written informed consent document\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Histologically confirmed FL, grades 1-3a\n* Relapsed after or failed to respond to at least two prior lines of systemic therapy and had received prior treatment with an anti-CD20-directed therapy\n* Prior treatment-related adverse events (AEs) must have recovered to grade ≤ 1 with the exception of alopecia and grade 2 peripheral neuropathy\n* At least one bi-dimensionally measurable lesion (≥ 1.5 cm in its largest dimension for nodal lesions, or ≥ 1.0 cm in its largest dimension for extranodal lesions within 6 weeks of screening by PET\u002FCT scans with diagnostic computed tomography \\[CT\\] scan. PET\u002Fmagnetic resonance imaging \\[MRI\\] scans may be allowed only if they are approved by the principal investigator \\[PI\\])\n* Aspartate aminotransferase and alanine aminotransferase ≤ 3 x the upper limit of normal (ULN)\n* Total bilirubin ≤ 1.5 x ULN; or total bilirubin ≤ 3 x ULN in patients with documented liver involvement or in patients with a documented history of Gilbert syndrome\n* Platelet count ≥ 75 000\u002Fmm\\^3 at any time during the screening window without requiring transfusion within 14 days prior to first dose of pirtobrutinib\n* Absolute neutrophil count ≥ 1000\u002Fmm\\^3 in the absence of growth factor support\n* Total hemoglobin ≥ 10 g\u002FdL at any time during the screening window without requiring transfusion within 21 days prior to first dose of pirtobrutinib\n* Patients who did not meet criteria for hematologic function because of extensive marrow involvement of non-Hodgkin lymphoma, splenic sequestration, and\u002For disease-related cytopenia (e.g., immune thrombocytopenia) could be enrolled into the study if they have platelet count ≥ 50,000\u002Fmm\\^3, absolute neutrophil count ≥ 750\u002Fmm\\^3, and hemoglobin ≥ 7.5 g\u002FdL after discussion with and confirmation by the PI\n* Activated partial thromboplastin time (or partial thromboplastin time) and prothrombin (or international normalized ratio) ≤ 1.5 ULN\n* Estimated creatinine clearance (CL) ≥ 30 mL\u002Fmin by Cockcroft-Gault formula: (140 - age) x body weight (kg) x 0.85 (if female) serum creatinine (mg\u002Fdl) x 72 or other institutional standard methods (e.g., based on nuclear medicine renal scan)\n* Negative serum pregnancy test at any time during the screening window for women of childbearing potential (WOCBP), defined as following: menarche and who are not postmenopausal (and 2 years of non-therapy-induced amenorrhea) or surgically sterile. Additionally, a negative serum pregnancy test is required within 3 days of initiating pirto\n* Fertile male and WOCBP patients must be willing to use highly effective contraceptive methods from the initiation of study treatment, until at least 3 months after the last dose of mosun or at least one month after the last dose of pirto, whichever occurs last\n\nExclusion Criteria:\n\n* Prior BTK inhibitor (BTKi) refractory disease defined as disease progression or recurrence during or within 6 months of prior BTKi therapy. If disease progression or recurrence occurs \\> 6 months after patients are off BTKi (e.g., due to intolerance), it is not considered as BTKi refractoriness. Patients with prior BTKi exposure but not meeting the criteria of BTKi refractoriness can be enrolled in this trial\n* Prior exposure to pirtobrutinib\n* CD3 T-cell engager exposed disease. However, these patients may be eligible if they stay in remission for at least 24 months after the last treatment with CD3 T-cell engager and have histologically confirmed CD20 expression on lymphoma at relapse or progression of disease\n* Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate within 4 weeks before first pirtobrutinib administration\n* Prior treatment with systemic immunotherapeutic agents for which the mechanism of action involves T cells, including but not limited to cytokine therapy and anti-CTLA-4, anti-programmed death (PD)-1 and anti-PD-ligand 1 therapeutic antibodies, within 12 weeks or 5 half-lives of the drug, whichever was shorter, before first pirtobrutinib administration\n* Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever was shorter, prior to first pirtobrutinib administration\n* Treatment with radiotherapy within 2 weeks prior to the first pirtobrutinib administration. If patients received radiotherapy within 4 weeks prior to the first pirtobrutinib administration, patients must have had at least one measurable lesion outside of the radiation field. Patients who had only one measurable lesion that was previously irradiated but subsequently progressed are eligible\n* History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T cell (CAR-T) therapy within 60 days of enrollment or presence of any of the following, regardless of prior SCT and\u002For CAR-T therapy timing:\n\n  * Active graft versus host disease (GVHD);\n  * Cytopenia from incomplete blood cell count recovery post-transplant;\n  * Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity \\> grade 1 from CAR-T therapy;\n  * Ongoing immunosuppressive therapy (\\> 20 mg prednisone or equivalent daily) or have been off immunosuppressive agents \\\u003C 2 months\n* Prior solid organ transplantation\n* Patients who cannot swallow oral medications\n* History of bleeding diathesis\n* Patients who experienced a major bleeding event on prior treatment with a BTKi\n* Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug\n* History of autoimmune disease, including but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis\n* Patients with history of macrophage activation syndrome\u002Fhemophagocytic lymphohistiocytosis (HLH)\n* Patients with history of confirmed progressive multifocal leukoencephalopathy\n* History of severe allergic or anaphylactic reactions to monoclonal antibody or BTKi therapy\n* History of other malignancy except for the following: history of second malignancy unless in remission for at least 2 years; in-situ carcinomas not requiring treatment intervention, non-melanoma skin cancer curatively treated, nonmetastatic breast, or nonmetastatic prostate cancer where hormonal therapy is being continued as standard of care are allowed\n* Current or past history of central nervous system (CNS) lymphoma\n* Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Patients with a history of stroke who had not experienced a stroke or transient ischemic attack in the past 2 years and had no residual neurologic deficits as judged by the investigator were allowed. Patients with a history of epilepsy who had no seizures in the past 2 years while not receiving any anti- epileptic medications were allowed\n* Significant cardiovascular disease defined as:\n\n  * Unstable angina or acute coronary syndrome within the past 2 months prior to enrollment;\n  * History of myocardial infarction within 3 months prior to enrollment;\n  * Documented left ventricular ejection fraction (LVEF) by any method of ≤ 40% in the 12 months prior to enrollment;\n  * ≥ grade 3 New York Heart Association (NYHA) functional classification system of heart failure;\n  * Uncontrolled or symptomatic arrhythmias\n* Significant active pulmonary disease (eg, bronchospasm and\u002For obstructive pulmonary disease)\n* Known active and uncontrolled bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to first pirtobrutinib administration\n* Known or suspected chronic active Epstein Barr virus infection\n* Known active cytomegalovirus (CMV) infection. Unknown or negative status are eligible\n* Recent major surgery within 4 weeks prior to first pirtobrutinib administration\n* Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below:\n\n  * Hepatitis B virus (HBV):\n\n    * Patients with positive hepatitis B surface antigen (HBsAg) are excluded\n    * Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require a negative hepatitis B polymerase chain reaction (PCR) evaluation before enrollment\n    * Patients who are HBV deoxyribonucleic acid (DNA) PCR positive will be excluded\n  * Hepatitis C virus (HCV): If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before enrollment. Patients who are hepatitis C RNA positive will be excluded\n* Patients who have tested positive for human immunodeficiency virus (HIV) are excluded due to risk of opportunistic infections with both HIV and BTK inhibitors. For patients with unknown HIV status, HIV testing will be performed at Screening and result must be negative for enrollment\n* Patients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist\n* Pregnant or breast-feeding women\n* Administration of live vaccination within 28 days of first administration of study drug","ALL","18 Years",{"count":19,"type":20},22,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial tests how well pirtobrutinib and mosunetuzumab work in treating patients with grade 1-3a follicular lymphoma (FL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Pirtobrutinib, a type of tyrosine kinase inhibitor, works by blocking the action of the Bruton tyrosine kinase (BTK) protein. The BTK protein signals cancer cells to multiply, and blocking it may help keep cancer cells from growing. It could also improve T cell fitness and decrease inflammation, therefore, may improve the efficacy and safety of T cell-based therapies, such as mosunetuzumab. Mosunetuzumab is a bispecific antibody that binds both T cells and the lymphoma cancer cells and harnesses T cells to interfere with the ability of cancer cells to grow and spread. Giving pirtobrutinib and mosunetuzumab together may kill more tumor cells in patients with relapsed or refractory grade 1-3a FL and potentially decreases some side effects of mosunetuzumab which are related to T cells being activated (e.g., cytokine release syndrome).",[26,27,28,29,30],"Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma","Recurrent Follicular Lymphoma","Refractory Follicular Lymphoma","RECRUITING","2026-06-02",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":35},"2025-11-17",{"date":39,"type":20},"2031-07-31",{"name":41,"class":42},"University of Washington","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100550085","phase-2-low-dose-mosunetuzumab-for-the-treatment-of-patients-with-indolent-b-cell-lymphoma-100550085","NCT06442475","Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma","Low Dose Mosunetuzumab for Indolent B-Cell Lymphoma","Inclusion Criteria:\n\n* 18 years or older at time of signing informed consent\n* Capable of understanding and providing written informed consent\n* Histologically confirmed indolent B-cell non-Hodgkin lymphoma with no prior therapy for lymphoma. (Prior peptide-based therapeutic vaccines are allowed.) Eligible histologies include:\n\n  * Follicular lymphoma (grade 1-2 or 3A)\n  * Marginal zone lymphoma\n* Ann Arbor stage II-IV disease\n* No prior therapy for lymphoma\n* Have low-tumor burden disease, defined by Groupe D'Etude des Lymphomes Folliculaires (GELF) criteria:\n\n  * Nodal or extranodal tumor mass \\\u003C 7 cm\n  * Involvement of less than 3 nodal sites with a diameter \\> 3 cm\n  * No systemic or B symptoms\n  * No splenomegaly \\> 16 cm by imaging\n  * No local risk of vital organ compression\n  * No pleural or peritoneal serous effusions\n  * No leukemic phase (\\> 5,0000\u002F uL circulating lymphocytes)\n  * No significant cytopenias defined as platelets \\\u003C 100,000\u002FuL, hemoglobin \\\u003C 10 g\u002FdL, or absolute neutrophil count (ANC) \\\u003C 1500\u002F uL\n* Have measurable nodal disease, including at least 1 disease site measuring at least 1.5 cm in longest dimension on CT or fludeoxyglucose F-18 (FDG)-PET, or a FDG-avid extranodal measurable site measuring at least 1.0 cm in longest dimension. Measurable disease also includes spleen size more than 13 cm in vertical length\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Creatinine clearance ≥ 50 mL\u002Fmin calculated by Cockcroft-Gault equation\n* Total bilirubin ≤ 1.5 x the upper limit of normal (ULN), except in patients with Gilbert's syndrome who may have a total bilirubin up to ≤ 3 x ULN\n* Aspartate aminotransferase (AST) ≤ 3 x the ULN\n* Alanine aminotransferase (ALT) ≤ 3 x the ULN\n* Gamma glutamyl transferase (GGT) ≤ 3 x the ULN\n* Negative serum or urine pregnancy test within 7 days of initiating mosunetuzumab for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year\n* Fertile male and woman of childbearing potential must agree to use highly effective contraceptive methods from start of treatment to at least 3 months after the last dose of mosunetuzumab\n\nExclusion Criteria:\n\n* History of severe allergic reaction to monoclonal antibody therapy\n* History of a second primary malignancy that could affect compliance with the protocol or interpretation of results except with permission of the principal investigator. Malignancies treated curatively or at low-risk of progressing at the judgment of the principal investigator (PI) may be included\n* Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection at study enrollment\n* Infection with human immunodeficiency virus (unless viral load is undetectable and CD4 count ≥ 200)\n* Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen \\[HbBsAg\\] serology):\n\n  * Patients with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is undetectable at the time of screening. These patients must be willing to undergo monthly DNA testing and appropriate antiviral therapy as indicated by institutional standards\n* Autoimmune disease requiring active therapy\n* History of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)\n* Evidence of significant concurrent disease or medical condition that could interfere with the conduct of the study, or put the patient at significant risk including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association class III or IV cardiac disease, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)\n* Ongoing systemic corticosteroid treatment, with the exception of corticosteroid use for other (non-tumor and non-immunosuppressive) indications up to a maximum of 10 mg\u002Fday of prednisone or equivalent\n* Prior use of any monoclonal antibody within 4 weeks before the first mosunetuzumab administration\n* Prior solid organ transplantation\n* Pregnant or breast-feeding women, or intending to become pregnant during the study or within 3 months of the last dose of mosunetuzumab",{"count":52,"type":20},20,[23],"This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.",[56,57,58,59,60,61,26,27,28],"Ann Arbor Stage II Follicular Lymphoma","Ann Arbor Stage II Marginal Zone Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage III Marginal Zone Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Ann Arbor Stage IV Marginal Zone Lymphoma","2026-03-10",{"date":64,"type":35},"2026-03-13",{"date":66,"type":35},"2024-08-29",{"date":68,"type":20},"2027-02-12",{"name":41,"class":42},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":43},"100430312","phase-2-acalabrutinib-and-obinutuzumab-for-the-treatment-of-previously-untreated-follicular-lymphoma-or-other-indolent-non-hodgkin-lymphomas-100430312","NCT04883437","Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas","An Open-Label Phase 2 Trial of Acalabrutinib Plus Obinutuzumab in Patients With Untreated, Low Tumor Burden Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas","Inclusion Criteria:\n\n* Men and women \\>= 18 years of age\n* Patients will need to have one of the following clinical scenarios:\n\n  * Previously untreated follicular lymphoma grade 1-3a with low tumor burden by Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria\n  * Previously untreated follicular lymphoma grade 1-3a with high tumor burden by GELF criteria but who are unable or unwilling to receive standard front-line treatment approaches\n  * Previously untreated marginal zone lymphoma, lymphoplasmacytic lymphoma, or any other indolent B-cell lymphoproliferative disorder with low tumor burden by GELF criteria or who are unable\u002Funwilling to receive more intensive front-line treatment\n  * Previously untreated mantle cell lymphoma who would otherwise be appropriate candidates for watchful waiting OR who have symptomatic disease but are not candidates for or decline standard induction approaches\n* Patients with previously untreated low tumor burden FL (criterion above) must have measurable and\u002For assessable disease defined as at least one involved lymph node or extranodal disease site that measures \\>= 1.5cm in greatest diameter\n* Patients who meet inclusion criteria above are eligible as long as they meet one of the following criteria for measurable\u002Fassessable disease:\n\n  * At least one involved lymph node or extranodal disease site measuring \\> 1.5cm in greatest diameter\n  * Pathologically-confirmed bone marrow or peripheral blood involvement that can be reassessed for response\n  * Pathologically confirmed splenic or extranodal involvement with at least one known site of disease remaining after diagnostic biopsy that can be reassessed (i.e., patients with splenic marginal zone lymphoma who complete splenectomy and have no other detectable disease would not be eligible)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Woman of childbearing potential (WOCBP) and men enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry for the duration of study participation, and for at least 2 days after the last dose of acalabrutinib or 18 months after the last dose of obinutuzumab, whichever is longer. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Women of childbearing potential must have a negative serum or urine pregnancy test prior to starting therapy\n* Willing and able to participate in all required evaluations and procedures in this study protocol\n* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information\n\nExclusion Criteria:\n\n* The presence or history of histologically transformed or co-existing high-grade or aggressive non-Hodgkin lymphoma\n* Confirmed active or prior central nervous system disease\n* Prior receipt of lymphoma-directed therapy or prior antibody-based therapy (except for anti-microbial therapy for infection-associated marginal zone lymphoma such as hepatitis C or H pylori)\n\n  * A short course of steroids is permitted for patients aside from those in the low tumor burden FL cohort. This course may be no more than 14 days and steroids must be discontinued (or tapered to =\\\u003C 10mg prednisone or equivalent) no later than 3 days after initiation of study treatment. Patients in the low tumor burden FL cohort may not receive corticosteroids as an anti-lymphoma therapy at any time before starting treatment\n* Prior malignancy (or any other malignancy requiring active treatment), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for \\>= 2 years or which will not limit survival to \\\u003C 5 years\n* Clinically significant cardiovascular disease such as symptomatic ventricular arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification. Note: Subjects with controlled, asymptomatic atrial fibrillation can enroll on study if deemed appropriate by the investigator\n* Has difficulty with or is unable to swallow oral medication, or has significant gastrointestinal disease that would limit absorption of oral medication\n* Known history of human immunodeficiency (HIV) or any active significant infection (e.g., bacterial, viral, or fungal) within 14 days of cycle 1. Patients with uncomplicated viral or bacterial infections that are being managed with oral antibiotics and\u002For supportive care alone are eligible\n* Known history of hypersensitivity or anaphylaxis to study drug(s) including active product or excipient components\n* Active bleeding or history of bleeding diathesis (e.g., hemophilia or von Willebrand disease)\n* Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura)\n* Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening\n* Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor\u002Finducer\n* Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists\n* Requires treatment with proton pump inhibitors (e.g, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Note: Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study\n* History of significant cerebrovascular disease\u002Fevent, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug. Patients with a transient ischemic attack which has resolved and for which there are no ongoing symptoms are eligible\n* Major surgical procedure within 28 days of first dose of study drug (not including a diagnostic procedure to make the lymphoma diagnosis). Note: If a subject had major surgery, they must have recovered adequately from any toxicity and\u002For complications from the intervention before the first dose of study drug\n* Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative polymerase chain reaction (PCR) and must be willing to undergo deoxyribonucleic acid (DNA) PCR testing during the study to be eligible. Those who are HBsAg positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result to be eligible and have completed appropriate anti-viral treatment. Those who are hepatitis C PCR positive will be excluded. Anti-viral therapy for patients with hepatitis-C associated marginal zone lymphoma will not be considered a prior anti-lymphoma treatment\n* Absolute neutrophil count (ANC) \\\u003C 1,000\u002FmcL\n* Platelet count \\\u003C 50,000\u002FmcL (Unless felt to be related to underlying disease)\n* Total bilirubin \\>= 1.5 x the upper limit of normal (ULN). Isolated bilirubin \\> 1.5 x ULN is permitted if the direct proportion is \\\u003C 35%\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) \\> 2.5 x ULN\n* Creatinine clearance =\\\u003C 40 mL\u002Fmin\u002F1.73m\\^2\n* Breastfeeding or pregnant\n* Concurrent participation in another therapeutic clinical trial",{"count":78,"type":20},49,[23],"This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib and obinutuzumab may kill more cancer cells.",[26,27,28,82,83,84,85,86],"Indolent Non-Hodgkin Lymphoma","Lymphoplasmacytic Lymphoma","Lymphoproliferative Disorder","Mantle Cell Lymphoma","Marginal Zone Lymphoma","2026-02-05",{"date":89,"type":35},"2026-02-09",{"date":91,"type":35},"2021-09-03",{"date":93,"type":20},"2027-01-15",{"name":95,"class":42},"Emory University",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":43},"100552334","phase-2-combination-of-zanubrutinib-rituximab-and-venetoclax-in-patients-with-previously-untreated-follicular-lymphoma-100552334","NCT06471738","Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma","Safety and Efficacy of Zanubrutinib in Combination With Rituximab and Venetoclax in Previously Untreated Follicular Lymphoma: An Open Label, Phase 2 Study","Inclusion Criteria:\n\n* A diagnosis of follicular lymphoma (grades 1, 2, or 3a), untreated\n* Stage II, III, or IV disease\n* Able and willing to provide written informed consent and to comply with the study protocol\n* at least one measurable disease\n* Must be in need of therapy as evidenced by at least one of the following criteria:\n* Presence of at least one B symptom:\n\n  * Fever (\\> 38 Celsius \\[C\\]) not due to infectious etiology\n  * Night sweats\n  * Weight loss \\> 10% in the past 6 months\n* Fatigue due to lymphoma\n* Splenomegaly (\\> 13 cm)\n* Compression syndrome (ureteral, orbital, gastrointestinal)\n* Any of the following cytopenias, due to lymphoma:\n\n  * Hemoglobin ≤ 10 g\u002FdL\n  * Platelets ≤ 100 x 10\\^9\u002FL\n  * Absolute neutrophil count (ANC) \\\u003C 1.5 x 10\\^9\u002FL\n* Pleural or peritoneal effusion\n* Lactate dehydrogenase (LDH) \\> upper limit of normal (ULN) or beta (B)2 microglobulin \\> ULN\n* Other lymphoma-mediated symptoms as determined by the treating physician\n\nExclusion Criteria:\n\n* ECOG≤ 2\n* Absolute neutrophil count (ANC) \\> 1.0 x 10\\^9\u002FL\n* Platelet count \\> 50 x 10\\^9\u002FL\n* Prothrombin time (PT)\u002Finternational normal ratio (INR) \\\u003C 1.5 x (upper limit of normal) ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time \\[aPTT\\]) \\\u003C 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonists, then INR ≤ 3.0)\n* Serum aspartate transaminase (AST) and alanine transaminase (ALT) \\\u003C 3 x upper limit of normal (ULN)\n* Creatinine clearance \\> 30 ml\u002Fmin calculated by modified Cockcroft-Gault formula\n* Bilirubin \\\u003C 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g\u002FdL\n* Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin \\[B-hCG\\]) pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study\n\nExclusion Criteria:\n\n* Known active central nervous system lymphoma or leptomeningeal disease\n* Follicular lymphoma with evidence of diffuse large B-cell transformation\n* Grade 3b follicular lymphoma\n* Any prior history of other malignancy besides follicular lymphoma\n* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy\n* Patients who have undergone major surgery within 14 days\n* The researchers believe that it is not advisable for the participant to take part in this trial.",{"count":104,"type":20},30,[23],"This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously untreated follicular lymphoma (FL) .",[56,26,58,60,27,28],"2024-07-16",{"date":110,"type":35},"2024-07-18",{"date":112,"type":35},"2024-07-10",{"date":114,"type":20},"2027-06-01",{"name":116,"class":42},"Chinese PLA General Hospital"]